Q3FY17 Results: Shilpa Medicare
Bhagyashree Vivarekar / 14 Feb 2017
The company reported a PAT figure of Rs 20.7 crore, which represents a sequential QoQ decline of 35.51 per cent and a YoY decline of 31.91 per cent.
On Tuesday, Shilpa Medicare Ltd. reported its consolidated results for the quarter ended on December 31, 2016.
The company's sales for this quarter, Q3FY17, came in at Rs 183.5 crore. This represents a 13.12 per cent sequential decline and 8.25 per cent YoY decline. Its operating profit (EBIT) for the recently concluded quarter amounted to Rs 27 crore and the EBIT margin stood at 14.71 per cent. In terms of the bottom-line, the company reported a PAT figure of Rs 20.7 crore, which represents a sequential QoQ decline of 35.51 per cent and a YoY decline of 31.91 per cent.
Shilpa Medicare Ltd. is an Indian pharmaceutical company. The company produces and export active pharmaceutical ingredients (API), fine chemicals, intermediates, herbal products and speciality chemical products. The company's oncology APIs and non-oncology APIs products are Bicalutamide, Bortezmib, Busulfan, Capecitabine, Carboplatin, Cisplatin, Abacavir Sulfate, Ambrozol HCI and many more. The company operates only in bulk drug and API business.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.